BioSpace News Archive

Sonendo ® Sponsors Inaugural Women in Endodontics Summit.

Scholar Rock today announced that its Board of Directors appointed Jay Backstrom, M.D., M.P.H., as Chief Executive Officer-Elect, effective September 20, 2022.

CHADD is proud to announce the appointment of Laurie Kulikosky, CAE, as the organization’s new Chief Executive Officer, effective October 17, 2022.

ImmuneSensor Therapeutics Inc. announced the Company has been awarded a $16.1 million Product Development Research Grant from the Cancer Prevention and Research Institute of Texas to advance Phase 2 studies evaluating IMSA101, a STING agonist, in combination with immune checkpoint inhibitors and radiotherapy for the treatment of metastatic solid tumor malignancies.

BiondVax Pharmaceuticals Ltd. provided encouraging updates related to the strategic research collaboration between BiondVax, the Max Planck Institute for Multidisciplinary Sciences, and the University Medical Center Göttingen towards the development of a pipeline of innovative alpaca–derived nanosized antibody therapies.

NEUWAY Pharma GmbH announced two new appointments in its senior leadership team: Dr Oliver Ernst, formerly NEUWAY’s Chief Operating Officer, was promoted to Chief Executive Officer, and Dr Thomas Christoph was appointed as new Chief Development Officer.

BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc. today announced the European Commission (EC) has granted marketing authorization for NULIBRY® (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.

Biomea Fusion, Inc. presented today “Oral menin inhibitor, BMF-219, displays a significant and durable reduction in HbA1c in a type 2 diabetes rat model”, the first of two oral presentations at the EASD Annual Meeting.

Think Research Corporation has signed multiple new contracts in the third quarter worth approximately $12.8 million.

Invitae and Praxis Precision Medicines , Inc. today announced that real-world clinical insights from Invitae’s Ciitizen platform were utilized as natural history data to support the submission of Praxis’ Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy (DEE).